Page last updated: 2024-08-26

bosentan anhydrous and Hepatorenal Syndrome

bosentan anhydrous has been researched along with Hepatorenal Syndrome in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Deray, G; Izzedine, H; Kheder-Elfekih, R; Thabut, D1
Baumelou, A; Izzedine, H1
Anand, R; Dashwood, M; Goodier, D; Harry, D; Holt, S; Jarmulowicz, M; Milner, P; Moore, K1

Other Studies

3 other study(ies) available for bosentan anhydrous and Hepatorenal Syndrome

ArticleYear
Endothelin-receptor antagonist/N-acetylcysteine combination in type 1 hepatorenal syndrome.
    Journal of hepatology, 2009, Volume: 50, Issue:5

    Topics: Acetylcysteine; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Free Radical Scavengers; Hepatorenal Syndrome; Humans; Male; Middle Aged; Sulfonamides; Treatment Outcome

2009
Renal failure in cirrhosis.
    The New England journal of medicine, 2010, Jan-07, Volume: 362, Issue:1

    Topics: Bosentan; Endothelin Receptor Antagonists; Endothelins; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Pyridines; Renal Insufficiency; Sulfonamides; Tetrazoles

2010
Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure.
    Gut, 2002, Volume: 50, Issue:1

    Topics: Acute Disease; Analysis of Variance; Animals; Antihypertensive Agents; Biomarkers; Bosentan; Cells, Cultured; Endothelin Receptor Antagonists; Endothelin-1; Galactosamine; Hepatorenal Syndrome; Male; Microscopy, Electron; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Renal Circulation; Statistics, Nonparametric; Sulfonamides; Up-Regulation

2002